ScholarLens Back to search
2015•Journal of HepatologyRequires access

P0800 : Effectiveness and safety of combination new regimens based on Sofosbuvir (SOFO) with Ribavirin (RBV), Daclatasvir (DAC) or Simeprevir (SIM) in difficult patients to treat infected with chronic hepatitis C (CHC)

B. Kutala, F. Mourri, Nathalie Boyer, Véronique Sitruk, Nathalie Giuily, Corinne Castelnau, Patrick Marcellin, Tarik Asselah

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Daclatasvir, Sofosbuvir, Simeprevir, Ribavirin, Medicine, Chronic hepatitis, Virology, Hepatitis C

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
P0800 : Effectiveness and safety of combination new regimens based on Sofosbuvir (SOFO) with Ribavirin (RBV), Daclatasvir (DAC) or Simeprevir (SIM) in difficult patients to treat infected with chronic hepatitis C (CHC) — Research Paper | ScholarLens